What's the expected price impact of biosimilar launches for stelara?

Stelara’s (ustekinumab) biosimilar price impact depends a lot on (1) the size of the product portfolio at launch, (2) uptake/contracting speed, (3) payer formulary placement, and (4) whether the biosimilar comes in at a discount to the reference product and how much interchangeability/autosubstitution is available in a given country.

That said, investors/market analysts generally expect U.S.-style biosimilar dynamics to look like this for a major biologic such as Stelara:

Typical “expected” impact (rule-of-thumb)

• ~10–30% price pressure within the first year after biosimilar launches, assuming reasonable payer uptake and multiple channel contracts.
• ~20–50% by ~2–3 years as more patients switch and formulary tiering tightens—especially if there are multiple biosimilars or strong competitive tendering.
• Reference brand list price may not fall much immediately, but net price (after rebates/discounts) often declines faster.

Why Stelara may land in the middle-to-upper range

Stelara is widely used (psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis) and has had substantial exposure to biosimilar competition historically. In markets where payers move quickly, major biologics often see mid-range to high net declines as channels re-optimize.

What could push it higher or lower

Higher price impact if:

• There are multiple competing biosimilars with aggressive contracting
• Payers implement step therapy / restrictive prior authorization
• Strong switching behavior by providers/health systems
• Rapid adoption in large government and commercial formularies

Lower price impact if:

• Biosimilar uptake is slow (narrow formulary placement)
• High patient prescriber resistance / administrative friction
• Limited competitive intensity (e.g., fewer launches or weaker list discounts)
• Greater reliance on co-pay or patient support programs for the reference product

If you want, I can narrow this to a more precise range

To tailor the estimate, tell me:

1. Which geography you mean (U.S., EU/UK, other)?
2. Are you asking about first-year impact or 2–3 year cumulative effect?
3. Which biosimilar(s) / launch timing you’re focused on (specific names or “at launch” broadly)?